as on March 4, 2026 at 2:11 am IST
Day's Low
Day's High
0.10%
Downside
1.69%
Upside
52 Week's Low
52 Week's High
19.73%
Downside
23.00%
Upside
Check Exelixis, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$11.0B
EPS (TTM)
3.3925
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.84%
PE Ratio (TTM)
15.84
Industry PE ratio
8.581171171171171
PEG Ratio
2.2685
EBITDA
921.8M
Revenue (TTM)
2.3B
Profit Margin
33.73%
Return On Equity TTM
35.53%
Track how Exelixis, Inc. P/E has moved over time to understand its valuation trends.
Exelixis, Inc. in the last 5 years
Lowest (13.26x)
December 31, 2025
Industry (8.58x)
March 3, 2026
Today (15.84x)
March 3, 2026
Highest (122.74x)
April 30, 2021
Today’s Price to Earnings Ratio: 15.84x
Compare market cap, revenue, PE, and other key metrics of Exelixis, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $11.0B | 92.36% | 15.84 | 33.73% | |
| BUY | $126.2B | 133.18% | 32.47 | 32.94% | |
| BUY | $44.2B | 125.24% | 142.88 | 8.45% | |
| NA | $35.1B | NA | 621.55 | 5.37% | |
| BUY | $82.6B | 77.02% | 18.83 | 31.41% |
The Exelixis, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Exelixis, Inc. investment value today
Current value as on today
₹1,10,148
Returns
₹10,148
(+10.15%)
Returns from Exelixis, Inc. Stock
₹4,643 (+4.64%)
Dollar Returns*
₹5,505 (+5.5%)
Based on 26 analysts
76.92%
Buy
19.23%
Hold
3.85%
Sell
Based on 26 analysts, 76.92% of analysts recommend a 'BUY' rating for Exelixis, Inc.. Average target price of $47
Get share price movements and forecasts by analysts on Exelixis, Inc..
What analysts predicted
14.17%UPSIDE
Target Price
$47
Current Price
$40.34
Analyzed by
26 Analysts
Target
$47.00
Exelixis, Inc. target price $47, a slight upside of 14.17% compared to current price of $40.34. According to 26 analysts rating.
Search interest for Exelixis, Inc. Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:10% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 20 October
Mon, 12:00 PM
-Exelixis announces detailed results from STELLAR-303 trial, showing zanzalintinib improves overall survival to 10.9 months versus regorafenib.
Mon, 08:18 PM
-Exelixis stock drops 12.17% after sharing detailed results from STELLAR-303 trial, despite positive overall survival findings.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
![]()
In the last 3 years, EXEL has outperformed top 5 stocks with highest market-cap in its industry
Profit Spike
![]()
Netprofit is up for the last 6 quarters, 117.97M → 244.52M (in $), with an average increase of 13.4% per quarter
Revenue Rich
![]()
Revenue is up for the last 4 quarters, 555.44M → 598.66M (in $), with an average increase of 2.5% per quarter
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 33.5% return, outperforming this stock by 27.1%
Price Dip
![]()
In the last 7 days, EXEL stock has moved down by -9.1%
| Organisation | Exelixis, Inc. |
| Headquarters | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
| Industry | Health Technology |
| CEO | Dr. Michael M. Morrissey Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Dana T. Aftab Ph.D. | Executive Vice President of Research & Development |
Dr. William Berg M.D. | Senior Vice President of Medical Affairs |
Mr. Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial |
Dr. Stefan Krauss Ph.D. | VP & Head of Business Development |
Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board |
Mr. Christopher J. Senner | Executive VP & CFO |
Ms. Susan T. Hubbard | Executive Vice President of Public Affairs & Investor Relations |
Dr. Brenda J. Hefti J.D., Ph.D. | Senior VP & General Counsel |
Dr. Anne Champsaur M.D. | Senior Vice President of Drug Safety |
Dr. Michael M. Morrissey Ph.D. | CEO, President & Director |
Exelixis, Inc. share price today is $40.34 as on . Exelixis, Inc. share today touched a day high of $41.02 and a low of $40.3.
Exelixis, Inc. share touched a 52 week high of $49.62 on and a 52 week low of $32.38 on . Exelixis, Inc. stock price today i.e. is trending at $40.34,which is 18.70% down from its 52 week high and 24.58% up from its 52 week low.
Exelixis, Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Exelixis, Inc. (EXEL) shares with as little as ₹92.074 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹920.74 in Exelixis, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Exelixis, Inc. share’s latest price of $40.34 as on March 3, 2026 at 8:41 pm IST, you will get 0.2479 shares of Exelixis, Inc.. Learn more about
fractional shares .
Exelixis, Inc. stock has given 92.36% share price returns and 25.56% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?